Cyton Triveritas and knoell announced the addition of the newest member of the knoell family of companies specializing in animal health services: knoell Animal Health LLC.

The U.S. company will provide regulatory and clinical trial expertise and services to support companies wishing to develop and register vaccines, novel products and pharmaceuticals for veterinary use in the U.S.

The knoell group has offered animal health services in the U.S. for many years, the announcement said. Now, with Triveritas — which was acquired by the knoell group earlier this year and is well known for its very experienced team working in the U.S., Europe and globally — the founding of a U.S. company is an important step in growing the business in the U.S. and globally.

According to Felix Knoell, director strategy and innovation for the knoell group, establishing the new knoell Animal Health company was a natural progression to consolidate the group’s presence in the U.S. and to rationalize the corporate identity. The new entity clearly links the knoell name and its animal health consultancy services. It has always been part of the knoell ethos to have local connections "on the ground" to liaise with clients and regulators, and companies of all types and all sizes will be able to benefit from this strong new local base in the U.S., the company said.

Dr. Karolina Bate, managing director of Cyton Biosciences and Triveritas, said, “2020 has been a tremendously exciting year for Cyton Triveritas and for knoell. At the start of the year, knoell acquired Triveritas, and the months since have seen our teams grow together and become stronger, as we are able not only to share our technical and regulatory knowledge but also to inspire and learn from each other in our professionalism and creative approaches to developing the business.

"Founding the new knoell Animal Health company in the U.S. we see as a strategic investment in the animal health sector for the knoell group and, more broadly, a recognition of the industry’s importance, identifying it as a growth sector," Bate said.

"We welcome this development for the company group and for our clients. We’ve worked on joint development and registrations in the U.S. and Europe on several occasions, and it therefore makes sense to be streamlining business practices at a high level to facilitate work across both regions as much as possible,” she added.

Cyton Biosciences Ltd. was established in 1997 as an independent, privately owned consultancy service based in Bristol, U.K.

As an independent, scientific partner, the knoell group supports clients by providing individual solutions tailored to individual requirements. The group researches, processes and evaluates scientific data and covers all scientific specialties. It compiles registration dossiers and submits them to national and international authorities.